Related references
Note: Only part of the references are listed.Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants
Christian Pecquet et al.
BLOOD (2019)
Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
Nico Gagelmann et al.
BLOOD (2019)
Comments on pre-fibrotic myelofibrosis and how should it be managed
Tiziano Barbui et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
Donal P. McLornan et al.
HAEMATOLOGICA (2019)
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
Natasha Szuber et al.
MAYO CLINIC PROCEEDINGS (2019)
Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
Rangit R. Vallapureddy et al.
BLOOD CANCER JOURNAL (2019)
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Naseema Gangat et al.
CLINICAL CANCER RESEARCH (2019)
Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo
Brittany Woods et al.
CLINICAL CANCER RESEARCH (2019)
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX
Claire N. Harrison et al.
BLOOD (2019)
Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)
Claire N. Harrison et al.
BLOOD (2019)
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
Lucia Masarova et al.
BLOOD (2019)
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia
Antonio Piga et al.
BLOOD (2019)
MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis
John Mascarenhas et al.
BLOOD (2019)
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
Claire N. Harrison et al.
BLOOD (2019)
Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes ( MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Pierre Fenaux et al.
BLOOD (2019)
Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)
Paula De Melo Campos et al.
BLOOD (2019)
A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
Aaron T. Gerds et al.
BLOOD (2019)
A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
Kristen Pettit et al.
BLOOD (2019)
Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
Aaron T. Gerds et al.
BLOOD (2019)
Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis
Natasha Szuber et al.
LEUKEMIA (2019)
ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis
Ying Guo et al.
LEUKEMIA (2019)
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
A. Pardanani et al.
LEUKEMIA (2018)
Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
A. Tefferi et al.
LEUKEMIA (2018)
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
How I treat myelofibrosis after failure of JAK inhibitors
Animesh Pardanani et al.
BLOOD (2018)
MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
Maura Nicolosi et al.
LEUKEMIA (2018)
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
Ayalew Tefferi et al.
LEUKEMIA (2018)
U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
Ayalew Tefferi et al.
LEUKEMIA (2018)
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
Ayalew Tefferi et al.
LEUKEMIA (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Lucia Masarova et al.
BLOOD (2018)
Bone marrow specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis
Anna Chorzalska et al.
BLOOD (2018)
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
Sebastien Jacquelin et al.
BLOOD (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
Terra L. Lasho et al.
BLOOD ADVANCES (2018)
Ruxolitinib-associated infections: A systematic review and meta-analysis
Federico Lussana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
Hui Yang et al.
BLOOD (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia
D. A. C. Fisher et al.
LEUKEMIA (2017)
Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis
Laure Gilles et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
A. Tefferi et al.
LEUKEMIA (2017)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
F. Passamonti et al.
LEUKEMIA (2017)
Genetic Risk Assessment in Myeloproliferative Neoplasms
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2017)
The thrombopoietin/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature
M. Zingariello et al.
BLOOD CANCER JOURNAL (2017)
miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6
Sebastiano Rontauroli et al.
ONCOTARGET (2017)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa et al.
LANCET HAEMATOLOGY (2017)
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Malte Asshoff et al.
BLOOD (2017)
Metformin targets multiple signaling pathways in cancer
Yong Lei et al.
CHINESE JOURNAL OF CANCER (2017)
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
Ilyas Chachoua et al.
BLOOD (2016)
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
Caroline Marty et al.
BLOOD (2016)
Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm
Yue Yang et al.
BLOOD (2016)
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms
Marito Araki et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis
Jean Grisouard et al.
BLOOD (2016)
JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms
Chi Hua Sarah Lin et al.
BLOOD CELLS MOLECULES AND DISEASES (2016)
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
Takafumi Shimizu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Thrombopoietin/TGF-1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis
Vittorio Abbonante et al.
STEM CELLS (2016)
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
Shannon Elf et al.
CANCER DISCOVERY (2016)
Targeted deep sequencing in primary myelofibrosis
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
Michael Deininger et al.
BLOOD (2015)
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Qiang Jeremy Wen et al.
NATURE MEDICINE (2015)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+Cells
Paola Guglielmelli et al.
PLOS ONE (2015)
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex
Anand Balasubramani et al.
NATURE COMMUNICATIONS (2015)
JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Maria Kleppe et al.
CANCER DISCOVERY (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Raajit Rampal et al.
BLOOD (2014)
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis
Ruggiero Norfo et al.
BLOOD (2014)
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
A. Tefferi et al.
LEUKEMIA (2014)
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Lorena Arranz et al.
NATURE (2014)
Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells
Meng Zhao et al.
NATURE MEDICINE (2014)
Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion
Ingmar Bruns et al.
NATURE MEDICINE (2014)
Megakaryocytes Contribute to the Bone Marrow-Matrix Environment by Expressing Fibronectin, Type IV Collagen, and Laminin
Alessandro Malara et al.
STEM CELLS (2014)
AKT is a therapeutic target in myeloproliferative neoplasms
I. Khan et al.
LEUKEMIA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
Terra L. Lasho et al.
BLOOD (2012)
ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Omar Abdel-Wahab et al.
CANCER CELL (2012)
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
A. Tefferi et al.
LEUKEMIA (2012)
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli et al.
BLOOD (2011)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
Francesco Passamonti et al.
BLOOD (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
O. Abdel-Wahab et al.
LEUKEMIA (2011)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Bone Marrow Morphologic Features in Polycythemia Vera With JAK2 Exon 12 Mutations
Meredith A. Lakey et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche
Simon Mendez-Ferrer et al.
NATURE (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia
Kais Hussein et al.
PLATELETS (2009)
Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis
Lilian Varricchio et al.
EXPERT REVIEW OF HEMATOLOGY (2009)
Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines
Oliver Bock et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Stefan O. Ciurea et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
The stem cell niches in bone
T Yin et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis
AM Vannucchi et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-β1 in the development of myelofibrosis
AM Vannucchi et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Osteoblastic cells regulate the haematopoietic stem cell niche
LM Calvi et al.
NATURE (2003)
Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis
JC Wang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Development of myelofibrosis in mice genetically impaired for GATA-1low expression (GATA-1low mice)
AM Vannucchi et al.
BLOOD (2002)
Involvement of the fibrogenic cytokines, TGF-β and bFGF, in the pathogenesis of idiopathic myelofibrosis
MC Le Bousse-Kerdilès et al.
PATHOLOGIE BIOLOGIE (2001)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
